Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK117 and Cetuximab in Second-Line R/M HNSCC
NCT06508606Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Started Aug 2024; status: completed.
02
Drugs
ligufalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06508606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508606.